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Methods: Between November 1985 and July 1995, 36 patients underwent 
allograft aortic valve replacement for endocarditis. The mean age of the 29 
men and seven women was 53 years (range 25 to 79 years). Previous 
procedures included mechanical (n = 9), bioprosthetic (n = 5), and 
allograft (n = 2) aortic valve replacement, aortic valvotomy (n = 1), and 
orthotopic heart transplantation ( = 1). Infecting organisms were Staph- 
ylococcus and Streptococcus species in 69% of patients and fungi in 6%. 
Intraoperative findings demonstrated valvular vegetations (n = 25), annu- 
lar abscesses (n = 25), and cusp destruction (n = 13). Complex reconstruc- 
tion of the aortic anulus was required in 25 patients, and associated 
procedures included mitral valve repair (n = 2), mitral valve replacement 
(n = 3), coronary artery bypass grafting (n = 8), repair ofventricular septal 
defect (n =4), left ventricular aneurysmectomy (n = 1), and repair of atrial 
septal defect (n = 1). Allograft valve insertion was performed by the 
scalloped technique in seven, intraaortic cylinder technique in 19, and 
allograft aortic root replacement in 10. Results: Follow-up was 100% 
complete at a mean of 2.6 _ 2.8 years after valve replacement. Operative 
mortality was 13.8%. Complications included low cardiac output (n = 10), 
bleeding (n = 2), myocardial infarction (n = 1), stroke (n = 1), renal 
insufficiency (n = 2), respiratory insufficiency (n = 3), and heart block (n = 8). 
Late echocardiogram ( ean 2.6 - 1.8 years) demonstrated grade III/IV aortic 
regurgitation i  five patients. There were seven late deaths (five cardiac, not 
valve-related; two noncardiac). No patient has had recurrence of endocarditis. 
Actuarial survival at 5 years was 53.1% - 11.5%. Univariate analysis demon- 
strated prosthetic valve endocarditis to adversely affect late survival (p = 0.04). 
Cumulative risk of reoperation at 5 years was 8.0% +- 5.6%. Conclusion: 
Allograft aortic valve replacement facilitated reconstruction of complex aortic 
valve endocarditis with a low reoperation rate and no recurrent endocarditis n
this series. (J Thorac Cardiovasc Surg 1997;113:285-91) 
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D espite advances in the ability to diagnose and medically treat both native and prosthetic aortic 
valve endocarditis, operation is often indicated be- 
fore complete resolution of active infection. At the 
same time that the incidence of rheumatic valvular 
disease is decreasing in the United States, the 
incidence of infective endocarditis is increasing. 
This may be due to an aging population with asso- 
ciated prevalence of structural valvular abnormali- 
ties, increasing numbers of patients with prosthetic 
heart valves or indwelling catheter/pacing systems 
(or both), the enlarging population of immunosup- 
pressed or immunodeficient patients, and the large 
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Table I. Patient characteristics 
NVE PVE p 
(n = 20) (n = 16) Value 
Age (yr) 51 _+ 13 57 _+ 17 0.2 
Age range (yr) 28 to 79 25 to 78 
Male 16 (80%) 13 (81%) 1.0 
AR 13 (65%) 14 (88%)* 
AS 1 (5%) 0 0.2 
Mixed AS/AR 6 (40%) 2 (13%) 
Preop. EF 0.63 + 0.06 0.56 _+ 0.1 0.03 
NYHA class III/IV 14 (70%) 15 (94%) 0.1 
Age is presented as mean -+ standard deviation and expressed in years. 
NVE, Native valve ndocarditis; PVE, prosthetic valve endocarditis; AR, 
aortic regurgitation; AS, aortic stenosis; EF, ejection fraction; NYHA, New 
York Heart Association. 
*Aortic regurgitation with prosthetic valve endocarditis refers to perival- 
vular leak. 
Table II. Causative organisms 
NVE PVE 
(n = 20) (n = 16) 
Staphylococcus* 7 (35%) 11 (69%) 
Streptococcus* 10 (50%) 3 (19%) 
Corynebacterium 0 1 (6%) 
Aspergillus 1 (5%) 0 
Candida albicans 0 1 (6%) 
Haemophilus influenzae 1 (5%) 0 
Culture negative 1 (5%) 0 
* Staphylococcus and So'eptococcus species innative versus prosthetic valve 
endocarditis (p - 0.07). 
number  of intravenous drug abusers. Because oper- 
ation is frequently required in the presence of active 
infection for uncontrol led sepsis, congestive heart 
failure, septic emboli, and prosthetic valve or fungal 
endocarditis, the surgeon may be confronted with 
extensive annular destruction and perivalvular ring 
abscesses that complicate insertion of a standard 
aortic valve prosthesis. Numerous operative tech- 
niques have been reported to manage these chal- 
lenging problems, including aortic valve replace- 
ment (AVR) with an allograft, which is said to have 
a lower rate of subsequent infection than mechani- 
cal prostheses or other bioprostheses. TM To deter- 
mine the early outcome of allograft AVR for com- 
plex infections, we reviewed our recent experience 
with allografts for aortic valve endocarditis. 
Patients and methods 
Patient characteristics. Between November 1985 and 
August 1995, 2699 patients underwent AVR at the Mayo 
Clinic. One hundred seventeen patients underwent AVR 
for active endocarditis. In 57 of these a mechanical 
prosthesis was used, in 24 a heterograft bioprosthesis, and 
in 36 a cryopreserved allograft aortic valve. Valve choice 
Table III. Prior aortic valve procedures (n = 17) 
No. 
Mechanical AVR* 7 
Mechanical AVR (Konno)* 2 
Bioprosthetic AVR 5 
Allograft AVR 2 
Aortic valvotomy 1 
A VR, Aortic valve replacement. 
*Konno-Rastan ortoventriculoplasty. 
Table IV. Operative procedures 
NVE (n = 20) PVE (n = 16) 
Isolated allograft AVR* 9 4 
Allograft AVR 
+ CABGt 4 4 
+ MV repair 1 1 
+MVR 1 2 
+LV aneurysmectomy 1 0 
+ASD repair 1 0 
+VSD repair 0 4 
+RVOT repair 0 1 
+LV perforation repair 1 0 
+Root enlargement 4 5 
Allograft AVR (scaUop):~ 5 2 
Allograft AVR (cylinder) 15 4 
Allograft AVR (root) 0 10 
NVE, Native valve endocarditis; PVE, prosthetic valve endocarditis; AVR, 
aortic valve replacement; CABG, coronary artery bypass grafting; MV, 
mitral valve; MVR, mitraI valve replacement; LV,, left ventricular; ASD, 
atrial septal defect; VSD, ventricular septal defect; RVOT, right ventricular 
outflow tract. 
*Isolated vs associated procedure b tween NVE and PVE (p = 0.03). 
?Patients may have had a combination f the above listed associated 
procedures. 
SAllograft implantation techniques in NVE vs PVE (p = 0.001). 
was dependent on the local anatomy, the amount of tissue 
destruction, and the surgeon performing the operation. 
This review focuses on the patients having allograft AVR. 
Patient characteristics are summarized in Table I and 
causative organisms are listed in Table II. All patients 
received antibiotic therapy selected on the basis of culture 
results. The single patient with a "negative" blood culture 
in the preoperative p riod had received arenal transplant; 
he had valvular vegetations and gross evidence of infec- 
tion at the time of operation despite the inability to 
culture an organism. 
The primary indication for AVR was persistent sepsis in 
7 (19%) patients, congestive heart failure in 23 (64%), 
peripheral embolization in 3 (8%), coronary artery embo- 
lization in 1 (3%), and fungal endocarditis in 2 (6%) 
patients. Heart block was noted before the operation in 4 
patients with prosthetic valve endocarditis and 1 patient 
with native valve endocarditis and necessitated temporary 
transvenous pacing. Five patients were operated on ur- 
gently because of acute hemodynamic collapse and car- 
diogenic shock. 
Previous aortic valve operations (n = 17) are shown in 
Table III. At the time of the current operation, allograft 
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Fig. 1. Actuarial patient survival after allograft AVR for complex endocarditis. Expected, Survival for an 
age-matched population; NVE, native valve endocarditis; PVE, prosthetic valve endocarditis. Absolute 
numbers of patients urviving are indicated at yearly intervals. 
AVR was the second AVR in 11 patients, the third AVR 
in 5 patients, the fourth AVR in 2 patients, and the fifth 
AVR in 1 patient. An additional patient had undergone 
previous orth0topic heart transplantation. Operations 
performed are shown in Table IV. 
Echocardiography. Preoperative Doppler echocardio- 
graphic examination showed aortic regurgitation in 27, 
aortic stenosis in 1, and mixed stenosis/regurgitation in 8
patients. Annular abscesses with or without valvular veg- 
etations were rioted in 25 patients and cusp perforation or 
destruction in i3 patients. Preoperative left ventricular 
ejection fraction by echocardiography ranged from 0.23 to 
0.75 (mean 0.61). Since 1988, intraoperative transesoph- 
ageal echocardiography as been used to assess operative 
results. All surviving patients underwent echocardio- 
graphic assessment of their allograft aortic valve before 
hospital dismissal. These studies were repeated at approx- 
imately 1-year intervals and the most recent echocardio- 
gram available was used for late follow-up. 
Operative findings and techniques. Standard cardio- 
pulmonary bypass techniques were used. The duration of 
cardiopulmonary bypass ranged from 78 to 346 minutes 
(mean 170 minutes) and the period of aortic occlusion 
ranged from 52 to 194 minutes (mean 118 minutes). 
Intermittent periods of circulatory arrest were required in 
2 patients. Operative findings demonstrated valvular veg- 
etations in 25 (69%) patients, annular abscesses in 25 
(69%), and cusp abnormalities in 13 (36%). Left ventricu- 
lar-aortic discontinuity was noted in 4 (20%) patients with 
native valve endocarditis and in 11 (69%) patients with 
prosthetic valve endocarditis. Allograft AVR insertion 
facilitated mitral valve reconstruction i 6 (17%) patients 
and ventricular septal repair in 4 (11%) patients; in these 
patients the anterior leaflet of the allograft was used to 
repair defects in the recipient mitral valve or in the 
septum. Two (6%) other patients required separate mitral 
Table V. Early complications of  allograft AVR for 
endocarditis* 
NVE (n : 20) PVE (n = 16) 
Bleeding (exploration) 1 (5%) 1 (6.3%) 
Low cardiac output 2 (10%) 8 (50%) 
Myocardial infarction 0 1 (6.3%) 
Heart block? 0 5 (31.3%) 
Stroke 1 (5%) 0 
Renal insufficiency 0 2 (12.5%) 
Respiratory insufficiency 0 3 (18.8%) 
NVE, Native valve endocarditis; PVE, prosthetic valve endocarditis. 
*Overall complications in native versus prosthetic valve endocarditis (p = 
0.049). 
tNecessitating placement of a permanent transvenous pacemaker. 
valve annuloplasty. Two (6%) patients underwent pericar- 
dial repair in addition to the use of the allograft: one 
patient with a defect in the dome of the left atrium and the 
other patient with a defect in the right ventricular outflow 
tract. Seven (19%) patients required intraaortic balloon 
support after cardiopulmonary b pass. 
The techniques of allograft aortic valve implantation 
were dictated by the pathologic findings at operation. In 
general, all infected and necrotic tissue was d6brided and 
the anulus was treated locally with phenol. Three allograft 
insertion methods have been used: the scalloped tech- 
nique (partial or complete removal of allograft aortic 
valve sinuses) (n = 7; 19%), the cylinder technique 
(retaining the allograft aortic sinuses) within the native 
aortic root (n = 19; 53%), and allograft aortic root 
replacement (n = 10; 28%). Mean size of the allograft 
aortic valve was 22 mm (internal diameter)(range 20to 28 
mm). The cryopreserved aortic allografts used in this 
study were supplied by Cryolife Cardiovascular, Inc., 
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Fig. 2. Cumulative risk of reoperation for all patients; the absolute numbers at risk are indicated. 
American Red Cross, and United Cryoinstitute. Procure- 
ment protocols were performed by each of their respective 
guidelines.9, 12
Follow-up. The 36 patients who underwent AVR with a 
cryopreserved allograft between November 1, 1985, and 
August l, 1995, constitute the patient cohort; Follow-up 
data included the most recent clinic or personal physician 
visit, correspondence by mail questionnaire, or telephone 
contact. Follow-up (100% complete) ranged from the day 
of the operation to 9.3 years (mean 2.6 years) and totaled 
94 patient-years. All review and patient contacts were 
coordinated by the first author. 
Data analysis. Continuous variables were compared in 
the two groups with two-sample t tests or with Wilcoxon 
rank sum tests when appropriate. Comparisons ofpropor- 
tions were made with X 2 tests or Fisher's exact tests. 
Changes in nominal variables within individuals from 
early to late follow-up were analyzed with sign tests. 
Survival and cumulative risk of reoperation were esti- 
mated by the Kaplan-Meier method. 13 Comparisons of 
survival curves were made with log rank tests. Survival 
data include all patients, and cumulative risk of reopera- 
tion was calculated for those patients who survived for the 
first 30 postoperative days. Data are expressed as mean +_ 
standard error of the mean. ValueS of p less than 0.05 
were considered to be statistically significant. 
Results 
Patient survival and morbidity. Overall opera- 
tive mortality (30-day or hospital mortality) was 
13.8%; risk was 10% for patients with native valve 
endocarditis and 18.8% for patients with prosthetic 
valve endocarditis. Causes of early mortality (n = 5) 
included sepsis in 2 patients and low cardiac output, 
myocardial infarction, and stroke in each of the 
remaining 3 patients. One early death occurred 
during the operation as a result of sepsis and shock. 
There were no early deaths related to the allograft 
AVR. 
There were 7 late deaths. Five were cardiac but 
not related to the allograft valve, and 2 were non- 
cardiac deaths. The cardiac causes of death were 
myocardial infarction (n = 3) and congestive 
heart failure (n = 2). One patient died of myelo- 
dysplastic syndrome and another of a traumatic 
subdural hematoma. Actuarial patient survivals 5 
years after the operation for native valve endocar- 
ditis and prosthetic valve endocarditis were 70.8% 
_+ 14:5% and 31.9% _+ 14.7%, respectively (p = 
0.04) (Fig. 1). At late follow-up, 92% of the 
surviving patients (n = 24) were in New York 
Heart  Association class I, 4% in class II, and 4% 
in class III. Prosthetic valve endocarditis was the 
only factor that adversely affected long-term sur- 
vival as determined by univariate analysis (p = 
0.04). 
Nonfatal complications are shown in Table V. No 
patient had recurrent endocarditis of the allograft 
aortic valve during the follow-up period. 
Aortic valve regurgitation. Early echocardiogra- 
phy performed before hospital dismissal showed no 
aortic regurgitation i 26 (81%) patients and grade 
I aortic regurgitation in 6 (19%) patients. Late 
echocardiography (mean 2.6 _+ 1.8 years) demon- 
strated no aortic regurgitation i 16 (50%) patients, 
grade I in 4 (12.5%) patients, grade II in 6 (18%) 
patients, grade III in 1 (3%) patient, and grade IV 
aortic regurgitation i  5 (16%) patients (p = 0.01; 
early vs late echocardiography). There was no dif- 
ference in late aortic regurgitation between the 
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Fig. 3A. Four-chamber view demonstrating two defects from endocarditis: one annular defect involving 
the anterior leaflet of the mitral valve and the other a left ventricular outflow tract defect involving the 
ventric:ular septum. 
patients with native valve endocarditis and pros- 
thetic valve endocarditis. Four patients with grade 
IV aortic regurgitation have required reoperation 
(discussed later). At late follow-up there was no 
evidence of allograft aortic valve stenosis; mean 
gradient was 17 _+ 11 mm Hg and mean valve area 
was 1.4 +_ 0.4 cm 3. 
Reoperation. Five patients required reoperation 
for al!ograft failure, 4 because of structural deteri- 
oration and resultant severe aortic regurgitation and 
1 because of the development of a pseudoaneurysm 
at the inferior suture line. In the latter patient, the 
reoperation occurred 2.3 months after the initial 
operation. The allograft was intact and the dehis- 
cence was presumably caused by residual necrotic 
native tissue. All patients who underwent reopera- 
tion had native valve endocarditis at the time of 
allograft AVR, and reoperations occurred at a mean 
of 3.8 years after AVR (range 2.3 months to 6.1 
years). The cumulative risk of reoperation 5 years 
after the operation was 8.0% _+ 5.6% (Fig. 2). 
Discussion 
All patients with aortic valve endocarditis, either 
native valve or prosthetic valve, require appropriate 
antibiotic treatment. Whereas patients with native 
valve endocarditis are frequently treated success- 
fully without an operation, patients with prosthetic 
valve infection usually need operative intervention 
because of difficulty eradicating infection with anti- 
biotics alone. 14'15 In addition, both fungal and 
staphylococcal endocarditis of the native aortic 
valve are usually treated with operation because of 
extensive annular destruction and abscess formation 
that is unlikely to be adequately treated without 
annular ddbridement and excision of all infected 
tissue. 
If operation can be delayed until infection has 
resolved, the likelihood of successful AVR with 
either a mechanical or biologic prosthesis is im- 
proved; operative mortality is lower and late survival 
is greater than in those operated on in the setting of 
active infection. ~6-!s When operation is indicated 
290 Dearani et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
February 1997 
) 
Fig. 3B. Circumferential reconstruction of theaortic root with the allograft aortic valve being used as an 
intraaortic cylinder. Note that the allograft anterior mitral leaflet is used to repair the ventricular septal 
defect and a portion of the allograft aortic wall is attached the recipient anterior mitral eaflet. 
with active valve infection, extensive annular de- 
struction and abscess formation make AVR chal- 
lenging. Small defects may be repaired with direct 
suture, but larger defects or loss of aortoventricular 
continuity necessitate patch repair with prosthetic 
material or autologous pericardium. 19' a0 
The use of the cryopreserved aortic valve allograft 
has practical advantages in the setting of AVR with 
active infection and annular abnormalities. The 
allograft is a biologic material that appears to be 
more resistant to infection than prosthetic material 
such as Dacron fabric. 17' is In addition, because of 
its contiguous aortic wall and anterior mitral leaflet, 
complex annular defects are more easily recon- 
structed after appropriate trimming of the allograft 
to conform to the residual defect. Figs. 3A and 3B 
illustrate how this technique can be performed. 
In our practice, we have used aortic valve allo- 
grafts selectively; approximately 5% of all patients 
undergoing AVR at our institution in the past 
decade received an allograft, and in this series of 
patients with aortic valve endocarditis, the allograft 
was used in 33% of all patients with aortic valve 
endocarditis during the same time interval. In a 
recent follow-up of our patients with allograft aortic 
valves, 2I we have noted that the risk of significant 
aortic regurgitation developing and subsequently 
necessitating reoperation begins to increase after 5 
years of follow-up, whereas others have shown the 
risk of structural deterioration of the allograft to 
occur later. 22-24 Similar early findings were noted in 
these patients in whom allografts were used for 
aortic valve endocarditis; the risk of reoperation was 
approximately 5% for allograft failure from struc- 
tural deterioration and 8% overall in the first 5 years 
after the operation. 
Follow-up in this review is not long enough to 
allow comment on the late results of allograft AVR 
for endocarditis. However, the overall low operative 
mortality, low early reoperation rate, and absence of 
recurrence of endocarditis for this group of patients 
with complicated infections is quite good when 
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compared with results in patients receiving a me- 
chanical or bioprosthetic valve under similar circum- 
stances.i0, 11, ts, 16 
We zl and others 25' 26 have described implantation 
techniques of allograft aortic valves previously. Al- 
though the specific findings at operation are the best 
guide to the technique of insertion ultimately used, 
we generally prefer to insert the allograft as an 
intraaortic cylinder in the setting of endocarditis 
after complete d6bridement of infected tissue and to 
preserve as much noninfected tissue as possible. The 
anulus and borders of the defect are then treated 
locally with phenol. We reserve allograft aortic root 
replacement for situations that necessitate native 
aortic root excision, for example, prosthetic valve 
infection with extensive annular destruction and 
resultant aortoventricular discontinuity. 
Although the present series is small and the 
follow-up period short (mean follow-up 2.6 years), 
we are encouraged by the acceptably low operative 
mortality and the absence of reinfection in patients 
managed wit]h aortic valve allografts. Clearly, late 
durability of the aortic valve allograft is less than 
that of a mechanical prosthesis and similar to the 
bioprosthesis, but the versatility of the allograft 
aortic valve and its resistance to infection make it 
our prosthesis of choice when active aortic valve 
infection is complicated by extensive destruction of 
contiguous tissue. 
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